Despite the lack of deep value, there is something else: 4D Molecular Therapeutics Inc (FDMT) Stock
Goldman raised the price target for the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) stock to “a Buy”. The rating was released on February 07, 2024, according to finviz. The research report from Cantor Fitzgerald has initiated the stock to Overweight, with a price target set at $32. The stock was upgraded by Leerink Partners, who disclosed […]
Is 4D Molecular Therapeutics Inc (FDMT) Stock worth its current valuation?
Goldman raised the price target for the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) stock to “a Buy”. The rating was released on February 07, 2024, according to finviz. The research report from Cantor Fitzgerald has initiated the stock to Overweight, with a price target set at $32. The stock was upgraded by Leerink Partners, who disclosed […]
What’s best: jumping in or staying out? 4D Molecular Therapeutics Inc (FDMT) Stock
Goldman raised the price target for the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) stock to “a Buy”. The rating was released on February 07, 2024, according to finviz. The research report from Cantor Fitzgerald has initiated the stock to Overweight, with a price target set at $32. The stock was upgraded by Leerink Partners, who disclosed […]
The idea of catching 4D Molecular Therapeutics Inc (FDMT) Stock might be a good one
Goldman raised the price target for the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) stock to “a Buy”. The rating was released on February 07, 2024, according to finviz. The research report from Cantor Fitzgerald has initiated the stock to Overweight, with a price target set at $32. The stock was upgraded by Leerink Partners, who disclosed […]
Consensus Analyst Estimated Price Target of $50.11 for 4D Molecular Therapeutics Inc (NASDAQ:FDMT) Stock
Goldman raised the price target for the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) stock to “a Buy”. The rating was released on February 07, 2024, according to finviz. The research report from Cantor Fitzgerald has initiated the stock to Overweight, with a price target set at $32. The stock was upgraded by Leerink Partners, who disclosed […]
Are Options A Good Investment Right Now? 4D Molecular Therapeutics Inc (FDMT) Stock
Goldman raised the price target for the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) stock to “a Buy”. The rating was released on February 07, 2024, according to finviz. The research report from Cantor Fitzgerald has initiated the stock to Overweight, with a price target set at $32. The stock was upgraded by Leerink Partners, who disclosed […]
With upside potential, 4D Molecular Therapeutics Inc (FDMT) Stock is well-positioned to grow
Goldman raised the price target for the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) stock to “a Buy”. The rating was released on February 07, 2024, according to finviz. The research report from Cantor Fitzgerald has initiated the stock to Overweight, with a price target set at $32. The stock was upgraded by Leerink Partners, who disclosed […]
4D Molecular Therapeutics Inc (NASDAQ:FDMT) Stock is trading Higher 62.55% From 200-Day SMA
Goldman raised the price target for the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) stock to “a Buy”. The rating was released on February 07, 2024, according to finviz. Historical Earnings Surprises and Revenue Forecasts Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock […]
Analysts Estimated Revenue of $2.06M in the current quarter for 4D Molecular Therapeutics Inc (NASDAQ:FDMT) Stock
Goldman raised the price target for the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) stock to “a Buy”. The rating was released on February 07, 2024, according to finviz. Historical Earnings Surprises and Revenue Forecasts Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock […]
Growing at an Unbelievable Rate: 4D Molecular Therapeutics Inc (FDMT) Stock
Goldman raised the price target for the 4D Molecular Therapeutics Inc (NASDAQ:FDMT) stock to “a Buy”. The rating was released on February 07, 2024, according to finviz. Historical Earnings Surprises and Revenue Forecasts Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock […]